Phenotypic drug screening in a human fibrosis model identified a novel class of antifibrotic therapeutics

Gerckens, Michael; Schorpp, Kenji; Pelizza, Francesco; Woegrath, Melanie; Reichau, Kora; Ma, Huilong; Dworsky, Armando-Marco; Sengupta, Arunima; Stoleriu, Mircea Gabriel; Heinzelmann, Katharina; Merl-Pham, Juliane; Irmler, Martin; Alsafadi, Hani N.; Trenkenschuh, Eduard; Sarnova, Lenka; Jirouskova, Marketa; Friess, Wolfgang; Hauck, Stefanie M.; Beckers, Johannes; Kneidinger, Nikolaus; Behr, Jürgen; Hilgendorff, Anne; Hadian, Kamyar; Lindner, Michael; Koenigshoff, Melanie; Eickelberg, Oliver; Gregor, Martin; Plettenburg, Oliver; Yildirim, Ali Oender und Burgstaller, Gerald (2021): Phenotypic drug screening in a human fibrosis model identified a novel class of antifibrotic therapeutics. In: Science Advances, Bd. 7, Nr. 52, eabb3673

Abstract

Fibrogenic processes instigate fatal chronic diseases leading to organ failure and death. Underlying biological processes involve induced massive deposition of extracellular matrix (ECM) by aberrant fibroblasts. We subjected diseased primary human lung fibroblasts to an advanced three-dimensional phenotypic high-content assay and screened a repurposing drug library of small molecules for inhibiting ECM deposition. Fibrotic Pattern Detection by Artificial Intelligence identified tranilast as an effective inhibitor. Structure-activity relationship studies confirmed N-(2-butoxyphenyl)-3-(phenyl)acrylamides (N23Ps) as a novel and highly potent compound class. N23Ps suppressed myofibroblast transdifferentiation, ECM deposition, cellular contractility, and altered cell shapes, thus advocating a unique mode of action. Mechanistically, transcriptomics identified SMURF2 as a potential therapeutic target network. Antifibrotic activity of N23Ps was verified by proteomics in a human ex vivo tissue fibrosis disease model, suppressing profibrotic markers SERPINE1 and CXCL8. Conclusively, N23Ps are a novel class of highly potent compounds inhibiting organ fibrosis in patients.

• Dokumententyp: Zeitschriftenartikel
• Fakultät: Chemie und Pharmazie > Department für Pharmazie - Zentrum für Pharmaforschung
• Themengebiete: 500 Naturwissenschaften und Mathematik > 540 Chemie
• ISSN: 2375-2548
• Sprache: Englisch